|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/22 Y-mAbs Therapeutics, Inc. 10-K 12/31/21 93:10M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.78M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 46K
3: EX-21.1 Subsidiaries List HTML 25K
4: EX-23 Consent of Expert or Counsel HTML 25K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 28K
14: R1 Document and Entity Information HTML 95K
15: R2 Consolidated Balance Sheets HTML 123K
16: R3 Consolidated Balance Sheets (Parenthetical) HTML 39K
17: R4 Consolidated Statements of Net Loss and HTML 98K
Comprehensive Loss
18: R5 Consolidated Statements of Changes in HTML 79K
Stockholders' Equity
19: R6 Consolidated Statements of Cash Flows HTML 110K
20: R7 Organization and Description of Business HTML 29K
21: R8 Basis of Presentation HTML 32K
22: R9 Summary of Significant Accounting Policies HTML 120K
23: R10 Product Revenue HTML 62K
24: R11 Net Loss Per Share HTML 50K
25: R12 Inventory HTML 43K
26: R13 Intangible Assets HTML 28K
27: R14 Accrued Liabilities HTML 46K
28: R15 License Agreements and Commitments HTML 159K
29: R16 Stockholders' Equity HTML 38K
30: R17 Share-Based Compensation HTML 109K
31: R18 Related Party Transactions HTML 29K
32: R19 Income Taxes HTML 141K
33: R20 Other Benefits HTML 28K
34: R21 Gain From Sale of Priority Review Voucher HTML 28K
35: R22 Summary of Significant Accounting Policies HTML 168K
(Policies)
36: R23 Summary of Significant Accounting Policies HTML 71K
(Tables)
37: R24 Product Revenue (Tables) HTML 57K
38: R25 Net Loss Per Share (Tables) HTML 48K
39: R26 Inventory (Tables) HTML 43K
40: R27 Accrued Liabilities (Tables) HTML 45K
41: R28 License Agreements and Commitments (Tables) HTML 146K
42: R29 Share-Based Compensation (Tables) HTML 103K
43: R30 Income Taxes (Tables) HTML 144K
44: R31 BASIS OF PRESENTATION - Accumulated deficit HTML 29K
(Details)
45: R32 BASIS OF PRESENTATION - Secondary public offering HTML 39K
(Details)
46: R33 BASIS OF PRESENTATION - Cash and cash equivalents HTML 28K
(Details)
47: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 34K
Concentration of Credit Risk (Details)
48: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 44K
Value Measurement (Details)
49: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 27K
Operating Leases (Details)
50: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 38K
Property and Equipment (Details)
51: R38 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 27K
Income Taxes (Details)
52: R39 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 54K
Revenue Recognition (Details)
53: R40 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 35K
Research and development (Details)
54: R41 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Other HTML 33K
policies (Details)
55: R42 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 62K
Recently issued accounting pronouncements
(Details)
56: R43 PRODUCT REVENUE - Discounts and Allowances HTML 64K
(Details)
57: R44 PRODUCT REVENUE - Concentrations (Details) HTML 37K
58: R45 NET LOSS PER SHARE - Basic and diluted (Details) HTML 53K
59: R46 NET LOSS PER SHARE - Anti-dilutive securities HTML 28K
(Details)
60: R47 Inventory (Details) HTML 35K
61: R48 Intangible Assets (Details) HTML 30K
62: R49 Accrued Liabilities (Details) HTML 40K
63: R50 LICENSE AGREEMENTS AND COMMITMENTS - SADA License HTML 86K
Agreement (Details)
64: R51 LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and HTML 64K
MabVax License Agreement (Details)
65: R52 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 47K
agreements (Details)
66: R53 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 65K
agreements (Details)
67: R54 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 35K
(Details)
68: R55 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 41K
maturities (Details)
69: R56 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 30K
and discount rate (Details)
70: R57 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 45K
Preferred Stock (Details)
71: R58 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 82K
non-employees (Details)
72: R59 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 40K
(Details)
73: R60 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 36K
74: R61 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 46K
75: R62 SHARE-BASED COMPENSATION - Stock-based HTML 41K
compensation expense (Details)
76: R63 SHARE-BASED COMPENSATION - Stock Option Valuation HTML 45K
(Details)
77: R64 SHARE-BASED COMPENSATION - Stock option activity HTML 67K
(Details)
78: R65 SHARE-BASED COMPENSATION - Stock option HTML 32K
unrecognized compensation (Details)
79: R66 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 55K
Activity (Details)
80: R67 Related Party Transactions (Details) HTML 43K
81: R68 INCOME TAXES - Loss before income taxes (Details) HTML 42K
82: R69 INCOME TAXES - Provision for (Benefit From) Income HTML 43K
Taxes (Details)
83: R70 INCOME TAXES - Reconciliation of Income Taxes HTML 53K
(Details)
84: R71 INCOME TAXES - Deferred assets (Liabilities) HTML 56K
(Details)
85: R72 INCOME TAXES - Net Operating Loss Carryforwards HTML 39K
(Details)
86: R73 INCOME TAXES - Uncertain tax positions (Details) HTML 34K
87: R74 Other Benefits (Details) HTML 29K
88: R75 Gain From Sale of Priority Review Voucher HTML 38K
(Details)
91: XML IDEA XML File -- Filing Summary XML 168K
89: XML XBRL Instance -- ymab-20211231x10k_htm XML 2.00M
90: EXCEL IDEA Workbook of Financial Reports XLSX 114K
10: EX-101.CAL XBRL Calculations -- ymab-20211231_cal XML 177K
11: EX-101.DEF XBRL Definitions -- ymab-20211231_def XML 637K
12: EX-101.LAB XBRL Labels -- ymab-20211231_lab XML 1.38M
13: EX-101.PRE XBRL Presentations -- ymab-20211231_pre XML 1.07M
9: EX-101.SCH XBRL Schema -- ymab-20211231 XSD 201K
92: JSON XBRL Instance as JSON Data -- MetaLinks 428± 622K
93: ZIP XBRL Zipped Folder -- 0001558370-22-002567-xbrl Zip 738K
 | Download this zipped .zip folder |
| Files: | ymab-20211231.xsd ymab-20211231_cal.xml ymab-20211231_def.xml ymab-20211231_lab.xml ymab-20211231_pre.xml ymab-20211231x10k.htm ymab-20211231x10k001.jpg ymab-20211231x10k002.jpg ymab-20211231x10k003.jpg ymab-20211231x10k004.jpg ymab-20211231x10k005.jpg ymab-20211231x10k006.jpg ymab-20211231x10k007.jpg ymab-20211231x10k008.jpg ymab-20211231x10k009.jpg ymab-20211231x10k011.jpg ymab-20211231x10k012.jpg ymab-20211231x10k013.jpg ymab-20211231x10k014.jpg ymab-20211231x10k015.jpg ymab-20211231xex21d1.htm ymab-20211231xex23.htm ymab-20211231xex31d1.htm ymab-20211231xex31d2.htm ymab-20211231xex32d1.htm ymab-20211231xex32d2.htm ymab-20211231xex4d4.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/06/21 Y-mAbs Therapeutics, Inc. 10-Q 3/31/21 76:6.3M Toppan Merrill Bridge/FA 2/19/21 Y-mAbs Therapeutics, Inc. 8-K:7,8,9 2/17/21 15:2.7M Toppan Merrill/FA 12/22/20 Y-mAbs Therapeutics, Inc. 8-K:1,9 12/17/20 11:674K Toppan Merrill/FA 11/05/20 Y-mAbs Therapeutics, Inc. 10-Q 9/30/20 68:6.7M Toppan Merrill Bridge/FA 10/08/20 Y-mAbs Therapeutics, Inc. 8-K:1,9 10/07/20 11:294K Toppan Merrill/FA 4/21/20 Y-mAbs Therapeutics, Inc. 8-K:1,9 4/15/20 2:348K Toppan Merrill/FA 12/19/19 Y-mAbs Therapeutics, Inc. 8-K:1,9 12/13/19 3:170K Toppan Merrill/FA 9/19/19 Y-mAbs Therapeutics, Inc. 8-K:1,9 9/13/19 2:129K Toppan Merrill/FA 9/07/18 Y-mAbs Therapeutics, Inc. S-1/A 5:4.4M Toppan Merrill-FA 8/24/18 Y-mAbs Therapeutics, Inc. S-1 31:12M Toppan Merrill-FA |